Byrnes MarieElena, Alzahrany Majed, Punia Vineet
Epilepsy Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Department of Neurology, King Abdulaziz University, Jeddah, Saudi Arabia.
Epilepsia Open. 2025 Feb;10(1):355-360. doi: 10.1002/epi4.13123. Epub 2024 Dec 27.
Generalized epilepsy is classically thought of as a disease of the young and adolescent, with rarely reported cases among older adults. We aimed to analyze management and outcomes in a population sparsely described in the literature through a retrospective single-center cohort design. After excluding individuals without follow-up, we identified 151 people ≥50 years at the time of electrographically confirmed generalized epilepsy. Just over a quarter were late-onset (≥26 years), and 77% were diagnosed with genetic generalized epilepsy (GGE). Active seizures (in the last year of follow-up) were present in 57% of individuals, despite most of them having experienced prolonged seizure remission periods (median 7 years) in the past. Only five people were off antiseizure medication (ASM) at their last appointment, with most on an average of 2 ASMs. The odds of active epilepsy at the last follow-up were significantly higher among those with polyspikes (odds ratio [OR] = 2.42; 95% confidence interval [CI] = 1.01-6.01), myoclonic seizure history (OR = 2.88, 1.23-6.96), and developmental delay (OR = 4.75, 1.45-19.3). The odds were 60% lower in older adults with family history (OR = 0.4, 0.17-5.68). Our findings suggest that most older adults with generalized epilepsy achieve years of seizure remission, but the likelihood of epilepsy resolution is low. PLAIN LANGUAGE SUMMARY: Generalized epilepsy is seldom seen in older adults. We looked at 151 patients diagnosed with generalized epilepsy over the age of 50 to see how they are managed and what influences their outcomes. We found that although these patients can control their seizures with medication, the chance that their epilepsy resolves is low. Patients with certain characteristics classically seen in an epilepsy called "Juvenile Myoclonic Epilepsy" (JME) may have a more intractable course.
全身性癫痫传统上被认为是一种发生于年轻人和青少年的疾病,在老年人中鲜有病例报道。我们旨在通过回顾性单中心队列设计,分析文献中描述较少的人群的治疗情况及预后。在排除无随访的个体后,我们确定了151例在脑电图证实为全身性癫痫时年龄≥50岁的患者。略多于四分之一的患者为晚发性(≥26岁),77%的患者被诊断为遗传性全身性癫痫(GGE)。尽管大多数患者过去经历过较长时间的癫痫缓解期(中位时间7年),但在随访的最后一年仍有57%的患者出现活动性癫痫发作。在最后一次就诊时,只有5名患者停用了抗癫痫药物(ASM),大多数患者平均使用2种ASM。在最后一次随访时,有多棘波(优势比[OR]=2.42;95%置信区间[CI]=1.01-6.01)、肌阵挛发作史(OR=2.88,1.23-6.96)和发育迟缓(OR=4.75,1.45-19.3)的患者活动性癫痫的几率显著更高。有家族史的老年人几率低60%(OR=0.4,0.17-5.68)。我们的研究结果表明,大多数老年全身性癫痫患者可实现数年的癫痫缓解,但癫痫缓解的可能性较低。通俗易懂的总结:全身性癫痫在老年人中很少见。我们观察了151例50岁以上被诊断为全身性癫痫的患者,以了解他们的治疗情况以及哪些因素会影响其预后。我们发现,尽管这些患者可以通过药物控制癫痫发作,但癫痫缓解的几率较低。具有某些在一种称为“青少年肌阵挛性癫痫”(JME)的癫痫中典型出现的特征的患者,病程可能更难治疗。